CClinicalTrials.gg
Not yet recruitingNCT07167199Updated Sep 30, 2026

Absorbable Staples Versus Conventional Skin Closure in Women Undergoing Cesarean Delivery

An interventional study of Subcuticular monocryl suture and Subcuticular absorbable staple using Insorb device in Pregnancy, sponsored by Inova Health Care Services. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Inova Health Care Services · Not applicable, Interventional, and Other

Updated Sep 30, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
237
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Despite the high numbers of cesareans being performed, scientific evidence behind which surgical techniques are best remains uncertain. Our objective is to determine if subcuticular absorbable staples improve operative time and wound cosmetics

Read the detailed description

This will be an open-label randomized controlled clinical trial. Women undergoing cesarean delivery will be randomized to have either standard wound closure with Monocryl suture or absorbable subcuticular staples placed by INSORB skin stapling device. The INSORB under the skin stapling device is FDA approved but not currently used as standard of care at Inova. We will exclude women with intraamniotic infection, immunosuppression, active skin infection, those unlikely to be followed-up after delivery, or unable to provide consent.

02

Conditions studied

  • Pregnancy
03

In context

Lead sponsor

Inova Health Care Services is the lead sponsor of 84 studies on the registry; 20 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • 18-50 years of age
  • Women ≥ 24 weeks viable gestation
  • Will be undergoing cesarean delivery

Exclusion criteria

Exclusion Criteria:

  • Patient unwilling or unable to provide consent.
  • No or very limited prenatal care or a non-resident patient who is unlikely to follow-up after delivery.
  • Immunosuppressed subjects: i.e., taking systemic immunosuppressant or steroids (e.g. transplant subjects; not including steroids for lung maturity), HIV with CD4 \<200, or other
  • Decision not to have skin closure (e.g. secondary wound closure, mesh closure)
  • Current skin infection
  • Coagulopathy
  • High likelihood of additional surgical procedure beyond cesarean (e.g. scheduled hysterectomy, tubal ligation, bowel or adnexal surgery)
  • Incarcerated individuals
  • Intraamniotic infection
  • Subjects participating on other treatment trials or studies that would interfere with the current study's primary outcome.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
237 participants (estimated)

Study arms

  • Active comparator
    Suture wound closure

    Absorbable Moncryl sutures for closure of cesarean skin incision

    Procedure: Subcuticular monocryl suture

  • Experimental
    Absorbable staple wound closure

    Staples will be applied as per the manufacturer's instructions intraoperatively using INSORB device manufactured by CooperSurgical.

    Device: Subcuticular absorbable staple using Insorb device

Interventions

  • ProcedureSubcuticular monocryl suture

    Under the skin suture placed by hand

  • DeviceSubcuticular absorbable staple using Insorb device

    Under the skin stapling device that delivers absorbable staples

06

What researchers measure

Primary outcomes

  1. Operating time

    Total time for the procedure

    Time frame: Time from the start of surgery through end of skin closure up to 8 hours

Secondary outcomes

  1. Wound Cosmesis

    A digital photograph of the incision will be obtained on wound check visit POD 5-10 days and 4-6 weeks post partum. Each photograph will be evaluated by independent blinded research staff using the Stony Brook Scar Evaluation Scale. These scores are totaled to obtain the final score. The Stony Brook Scar Evaluation will score the scar from 0-5 where 5 shows significant healing.

    Time frame: Up to six weeks post partum

  2. Post Operative Pain

    Analog pain scale ranging from 0-10. This is a standard question that nurses as during the post partum period while in the hospital and clinic/nursing visits. The numerical score will be recorded from the patient's chart. A score of 0 means no pain, and 10 means the worst pain.

    Time frame: up to 3 days post-operatively

Other outcomes

  1. Number of Adverse Events

    Allergic reactions: anaphylaxis, angioedema, skin rashes, including Stevens Johnson and Toxic Epidermal Necrolysis

    Time frame: Up to 6 weeks post-partum

  2. Number of participants with any unscheduled postpartum visit

    Any additional postpartum clinic appointments for medical or clinical concerns beyond the routinely scheduled visits. Participants are counted once, regardless of number or type of visits

    Time frame: up to 30 days post-operatively

  3. Skin Closure Time in Minutes

    Minutes it takes for closure of the skin at time of surgery

    Time frame: Time from start of skin closure to end of skin closure up to 2 hours

07

Study locations

1 site
  • Inova Fairfax Medical Campus
    Falls Church, Virginia 22042, United States
    • Antonio Saad, MD · Contact · antonio.saad@inova.org · 706-776-6040
    • Michelle L Cassidy, PhD, RN · Contact · michelle.cassidy@inova.org · (703) 776-4600
    • Antonio Saad, MD · Principal investigator
    • Elle Murrin, MD · Sub investigator
    • Maggie Wong, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Start date
Aug 1, 2026→Nov 1, 2026
Sep 30, 2026
Primary completion
Sep 1, 2027→Sep 1, 2028
Sep 30, 2026
Study completion
Sep 1, 2027→Sep 1, 2028
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Start date Aug 1, 2026→Nov 1, 2026
    Primary completion Sep 1, 2027→Sep 1, 2028
    Study completion Sep 1, 2027→Sep 1, 2028

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07167199
Lead sponsor
Inova Health Care Services
Responsible party
Sponsor
First posted
Sep 11, 2025
Start date
Nov 1, 2026 (estimated)
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Antonio Saad, MD
Contact
antonio.saad@inova.org
(703) 779-6040
Michelle L Cassidy, PhD, RN
Contact
michelle.cassidy@inova.org
(703) 776-4600
Antonio Saad, MD
principal investigator · Inova Fairfax Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion